New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation.

TitleNew autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation.
Publication TypeJournal Article
Year of Publication2013
AuthorsDaikeler T, Labopin M, Ruggeri A, Crotta A, Abinun M, Hussein AA, Carlson K, Cornillon J, Diez-Martin JL, Gandemer V, Faraci M, Lindemans C, O'Meara A, Mialou V, Renard M, Sedlacek P, Sirvent A, Socie G, Sora F, Varotto S, Sanz J, Voswinkel J, Vora A, M Yesilipek A, Herr A-, Gluckman E, Farge D, Rocha V
JournalBlood//Blood
Volume121
Issue6
Pagination1059 - 64
Date Published2013
ISBN Number1528-0020
Other Numbersa8g, 7603509
Keywords*Autoimmune Diseases/et [Etiology], *Cord Blood Stem Cell Transplantation/ae [Adverse Effects], *Outcome Assessment (Health Care)/sn [Statistics & Numerical Data], *Risk Assessment/sn [Statistics & Numerical Data], Adolescent, Adult, Aged, Antibodies, Monoclonal, Murine-Derived/tu [Therapeutic Use], Autoimmune Diseases/dt [Drug Therapy], Child, Child, Preschool, Cyclosporine/tu [Therapeutic Use], Female, Follow-Up Studies, Humans, Immunologic Factors/tu [Therapeutic Use], Immunosuppressive Agents/tu [Therapeutic Use], Infant, Male, Middle Aged, Multivariate Analysis, Outcome Assessment (Health Care)/mt [Methods], Retrospective Studies, Risk Assessment/mt [Methods], Risk Factors, Steroids/tu [Therapeutic Use], Survival Analysis, Young Adult
Abstract

To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% +/- 1% at 1 year and 6.6% +/- 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P

Notify Library Reference ID4220

Related Incidents